CoChat

Evaluation of the Safety, Tolerability, and Pharmacokinetic Profiles of TP0473292 (TS-161), A Prodrug of a Novel Orthosteric mGlu2/3 Receptor Antagonist TP0178894, in Healthy Subjects and Its Antidepressant-Like Effects in Rodents

Open access

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Abstract

Background: TP0473292 (the active ingredient of TS-161) is a prodrug of a novel metabotropic glutamate (mGlu) 2/3 receptor antagonist being developed for the treatment of patients with depression. This study evaluated the safety, tolerability, and pharmacokinetics of orally administered TS-161 in healthy subjects. Methods: This was a first-in-human, phase 1, randomized, double-blind, placebo-controlled, single-ascending dose (15–400 mg TS-161) and 10-day multiple-ascending dose (50–150 mg TS-161) study in healthy subjects, conducted from June 2019 through February 2020. Plasma and urine concentrations of the prodrug and its metabolites, and cerebrospinal fluid (CSF) concentrations of the active metabolite TP0178894 were measured to evaluate the pharmacokinetic profiles after oral administration of TS-161. Results: Following single and multiple doses, TP0473292 was extensively converted into its active metabolite TP0178894. Plasma concentrations of TP0178894 reached peak (Cmax) within 5 hours post dose and declined with a t1/2 <13 hours. Plasma exposures of TP0178894 increased with increasing dose. TP0178894 penetrated into CSF and reached a Cmax of 9.892 ng/mL at a single dose of 100 mg, which was comparable with IC50 values of antagonist activity at mGlu2/3 receptors. The most frequently observed adverse events that showed exposure-related incidence during the study were nausea, vomiting, and dizziness. Conclusions: The mGlu2/3 receptor antagonist prodrug TP0473292 is safe and well-tolerated, is orally bioavailable in humans with extensive conversion into the active metabolite TP0178894 with sufficient CSF penetration to exert the anticipated pharmacological effects, and is a promising candidate for further clinical development in treatment of patients with depression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ijnp/pyab062

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Chemical structures of TP0473292 and TP0178894, and in vivo pharmacological profiles of TP0473292. (A) Chemical structure of TP0473292; (B) Chemical structure of TP0178894; (C) Effect of oral administration (p.o.) of TP0473292 on mGlu2/3 receptor agonist, LY379268-induced hypolocomotion in rats. Locomotor activity was measured for 30 min after subcutaneous (s.c.) administration of LY379268. Data represent mean ± SE (n = 8/group). ##P < .01 compared with 0.5% methyl cellulose 400 (MC) group (Student’s t-test), **P < .01 compared with LY379268-treated 0.5% MC group (Steel’s test); (D) Effect of oral administration (p.o.) of TP0473292 on immobility time in the forced swimming test of rats. Immobility time during the forced swimming test was measured for 5 min. Data represent mean ± SE (n = 9 – 10/group). **P < .01 compared with vehicle group (Dunnett’s test); (E) Effect of oral administration (p.o.) of TP0473292 on depressive-like behavior of corticosterone (CORT) treatment model of rats. Depressive-like behavior (increased immobility) was induced by treating rats with CORT (20 mg/kg) subcutaneously (s.c.) for 21 days, and the forced swimming test was conducted 2 days after the final CORT injection. Immobility time during the forced swimming test was measured for 10 minutes. Data represent mean ± SE (n = 8/group). ##P < .01 compared with control group (Student’s t test), **P < .01 compared with vehicle-treated group (Dunnett’s test).
Figure 1. Chemical structures of TP0473292 and TP0178894, and in vivo pharmacological profiles of TP0473292. (A) Chemical structure of TP0473292; (B) Chemical structure of TP0178894; (C) Effect of oral administration (p.o.) of TP0473292 on mGlu2/3 receptor agonist, LY379268-induced hypolocomotion in rats. Locomotor activity was measured for 30 min after subcutaneous (s.c.) administration of LY379268. Data represent mean ± SE (n = 8/group). ##P < .01 compared with 0.5% methyl cellulose 400 (MC) group (Student’s t-test), **P < .01 compared with LY379268-treated 0.5% MC group (Steel’s test); (D) Effect of oral administration (p.o.) of TP0473292 on immobility time in the forced swimming test of rats. Immobility time during the forced swimming test was measured for 5 min. Data represent mean ± SE (n = 9 – 10/group). **P < .01 compared with vehicle group (Dunnett’s test); (E) Effect of oral administration (p.o.) of TP0473292 on depressive-like behavior of corticosterone (CORT) treatment model of rats. Depressive-like behavior (increased immobility) was induced by treating rats with CORT (20 mg/kg) subcutaneously (s.c.) for 21 days, and the forced swimming test was conducted 2 days after the final CORT injection. Immobility time during the forced swimming test was measured for 10 minutes. Data represent mean ± SE (n = 8/group). ##P < .01 compared with control group (Student’s t test), **P < .01 compared with vehicle-treated group (Dunnett’s test).CC BY · PubMed Central
Figure 2. Mean plasma concentration-time profiles of (A) TP0473292 in Part A following single-ascending dose (SAD) under fasted conditions, (B) TP0178894 in Part A (SAD, fasted), (C) TP0473292 on Day 10 in Part C following multiple-ascending dose (MAD) under fed conditions, and (D) TP0178894 on Day 10 in Part C (MAD, fed). Figures are presented as the mean + SD. Figures are presented as the mean + SD (n = 6).
Figure 2. Mean plasma concentration-time profiles of (A) TP0473292 in Part A following single-ascending dose (SAD) under fasted conditions, (B) TP0178894 in Part A (SAD, fasted), (C) TP0473292 on Day 10 in Part C following multiple-ascending dose (MAD) under fed conditions, and (D) TP0178894 on Day 10 in Part C (MAD, fed). Figures are presented as the mean + SD. Figures are presented as the mean + SD (n = 6).CC BY · PubMed Central
Figure 3. Mean plasma concentration-time profiles of TP0178894 and TP0473292, and cerebrospinal fluid (CSF) concentration-time profiles of TP0178894 following a single oral administration of 100 mg TS-161 under fasted conditions. Figure is presented as the mean ± SD. Figure is presented as the mean +/- SD (n = 6).
Figure 3. Mean plasma concentration-time profiles of TP0178894 and TP0473292, and cerebrospinal fluid (CSF) concentration-time profiles of TP0178894 following a single oral administration of 100 mg TS-161 under fasted conditions. Figure is presented as the mean ± SD. Figure is presented as the mean +/- SD (n = 6).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Research works printed but not linked: 2

  1. Gadient, 2012, Safety, pharmacokinetic and pharmacodynamic profile of BCI-632, a selective metabotropic glutamate 2/3 receptor antagonist, in healthy human subjects
  2. Sheffler, 2019, In vitro and in vivo characterization of group II mGlu receptor negative allosteric modulators as an alternative to ketamine for depression

Cited by

Metadata

Authors
Watanabe, M., Marcy, B., Hiroki, A., Watase, H., Kinoshita, K., Iijima, M., Marumo, T., Zarate, C. A., & Chaki, S.
Affiliations
  • Taisho Pharmaceutical R&D Inc., Morristown, New Jersey, USA
  • Taisho Pharmaceutical (Japan) (JP)
  • National Institutes of Health (US)
Corresponding author
Watanabe, Mai
Venue
International Journal of Neuropsychopharmacology
Published
2021-09-17
Volume
25
Issue
2
Pages
106-117
ISSN
  • 1461-1457 (ISSN-L)
  • 1469-5111
OpenAlex
W3201089702
Cited by
22
References
33
Citations by year
2026: 3 · 2025: 1 · 2024: 2 · 2023: 8 · 2022: 7 · 2021: 1
FWCI
2.63
Type
journal article
Language
en
Open access
Locations
  • The International Journal of Neuropsychopharmacology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Taisho Pharmaceutical Co., Ltd
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
Keywords
prodrugs, mGluR2/3, depression treatment, pharmacokinetics, cerebrospinal fluid penetration, oral bioavailability, first-in-human safety, tolerability, antidepressant-like effects
MeSH terms
Administration, Oral, Adolescent, Adult, Animals, Antidepressive Agents, Depression, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Male, Middle Aged, Prodrugs, Rodentia, Receptors, Metabotropic Glutamate, Area Under Curve, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.